Inhibrx, Inc. (NASDAQ:INBX – Get Rating) stock rose 6.3% during trade on Monday. The company traded as high as $22.81 and last traded at $22.81. About 43,426 shares traded during mid-day trading, down 89% from the average daily volume of 412,730 shares. The stock had previously closed at $21.45.
Wall Street analyst ponders
A number of equity analysts have recently commented on INBX stock. JMP Securities lowered its price target on Inhibrx shares to USD 35.00 from USD 40.00 and gave the stock a “Market Outperform” research report on Wednesday, March 8th. Credit Suisse Group revised a research report on Tuesday, March 7th to “Outperform” and issued a price target of $46.00 for shares of Inhibrx.
Inhibrx stock performance
The company has a market cap of $1.03 billion, a P/E of -6.51 and a beta of 2.96. The company has a quick ratio of 10.17, a current ratio of 10.17 and a debt to equity ratio of 3.54. The stock’s 50-day moving average price is $24.03 and its 200-day moving average price is $24.99.
Insider buying and selling
In related news, insider Brendan P. Eckelman sold 32,895 shares of the company’s stock in a transaction on Tuesday, Jan. 3. The shares sold at an average price of $23.77 for a total transaction of $781,914.15. Following the transaction, the insider now owns 2,122,658 shares of the company’s stock valued at $50,455,580.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission available at this hyperlink. In related news, insider Brendan P. Eckelman sold 28,750 shares of the company’s stock in a transaction on Wednesday, February 1. The shares sold at an average price of $24.73 for a total transaction of $710,987.50. Following the transaction, the insider now owns 2,086,803 shares of the company’s stock valued at $51,606,638.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission available at this hyperlink. Also on Tuesday, Jan. 3, insider Brendan P. Eckelman sold 32,895 shares of the company’s stock in a transaction. The stock sold at an average price of $23.77 for a total transaction of $781,914.15. Following the transaction, the insider now directly owns 2,122,658 shares of the company’s stock valued at approximately $50,455,580.66. The disclosure for this sale can be found here. During the most recent quarter, insiders sold 128,310 shares of the company’s shares for $3,203,546. 25.80% of the shares are owned by company insiders. Institutional investors rely on Inhibrx
Several institutional investors and hedge funds have recently bought and sold shares in the company. MetLife Investment Management LLC increased its stake in Inhibrx by 3.0% during the fourth quarter. MetLife Investment Management LLC now owns 17,746 shares of the company’s stock valued at $437,000 after purchasing an additional 519 shares during the period. Squarepoint Ops LLC increased its stake in Inhibrx by 5.0% during the fourth quarter. Squarepoint Ops LLC now owns 15,299 shares of the company’s stock valued at $377,000 after purchasing an additional 732 shares during the period. Voya Investment Management LLC increased its stake in Inhibrx by 6.7% during the fourth quarter. Voya Investment Management LLC now owns 12,557 shares of the company’s shares valued at $309,000 after purchasing an additional 784 shares during the period. HighTower Advisors LLC increased its stake in Inhibrx by 0.6% during the fourth quarter. HighTower Advisors LLC now owns 132,708 shares of the company’s stock valued at $3,271,000 after purchasing an additional 808 shares during the period. Finally, Amalgamated Bank increased its stake in Inhibrx by 18.1% during the fourth quarter. Amalgamated Bank now owns 5,452 shares of the company’s stock valued at $134,000 after purchasing an additional 835 shares during the period. Institutional investors own 72.79% of the company’s shares.
Inhibrx company profile
(received rating)
Inhibrx, Inc, a clinical-stage biotechnology company, is focused on developing a pipeline of novel biological therapeutic candidates. The Company’s therapeutic candidates include INBRX-109, a tetravalent death receptor 5 agonist in Phase 2 clinical trials for the treatment of cancers such as chondrosarcoma, mesothelioma and pancreatic adenocarcinoma; INBRX-105, a tetravalent programmed death ligand 1 conditional agonist and a 4-1BB conditional agonist in Phase 1 clinical trials for the treatment of patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1-antitrypsin (AAT)-Fc fusion protein therapeutic candidate that is in Phase 1 clinical trials for use in treating patients with AAT deficiency.
Selected items
Receive News & Ratings for Inhibrx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inhibrx and related companies with MarketBeat.com’s FREE daily email newsletter .
